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Abstract : The extended acute myocardial ischemia (AMI) results in cardiac myocytes death. In the present study,
we show that lactam pyridine derivative, SK-D80375, have the effects on cell survival in hypoxic cardiomyocytes
and might be used as an anti-ischemic drug. The lactam pyridine derivatives are inhibitors of the late sodium current,
which decreases sodium-dependent intracellular calcium overload in ischemia/reperfusion-injured hearts. We found
that pretreatment with SK-D80375 significantly decreased the level of intracellular Ca
2+
 and the expression level of
the Na
+
-Ca
2+
 exchanger by 39±2.5% and 19±0.5%, respectively in hypoxic cardiomyocytes compared to untreated
controls. In addition, the expression level of sarcoplasmic reticulum Ca
2+ 
ATPase 2a was significantly increased by
37±1.5% in SK-D80375-treated hypoxic cardiomyocytes compared to untreated controls. The induction of Hsp70
was observed in SK-D80375-treated hypoxic cardiomyocytes with dose-dependent manner and the highest level of
Hsp70 was induced at the concentration of 2.5 µM SK-D80375. The echocardiographic analysis showed that heart
function was significantly improved in SK-D80375-injected ischemic hearts. These results demonstrate that lactam
pyridine derivative, SK-D80375, have beneficial effects on hypoxia-induced cell death, therefore, might be used as
a novel anti-ischemia drug. 
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1. Introduction
Acute myocardial infarction (AMI) is a leading cause of
death in developed countries. Myocardial ischemia is known to
produce changes in cardiac function, metabolism and
ultrastructure.
1,2
 The effect of hypoxia may be more complex
because hypoxia have direct effects on the cardiovascular
system and may cause cardiac ischemia. Hypoxia induces
physiological responses such as, cell proliferation and vascular
remodeling,
3
 which is due to an intracellular Ca
2+
overload. In
fact, ischemia is associated with unbalances of cellular Ca
2+
 and
Na
+
 homeostasis.
4,5 
It is well known that Ca
2+
 homeostasis within the cardiac
myocyte is controlled by regulatory proteins in sarcolemmal
and sarcoplasmic reticulum (SR) membranes.
6,7
 The Ca
2+
pump including NCX, PMCA4 and CREM plays a major role
in Ca
2+
 homeostasis and contributes to abnormal intracellular
Ca
2+
 handling in a failing heart.
8,9
 Ca
2+
 enters the cell via the L-
type Ca
2+
 channel when the sarcolemmal membrane is
depolarized.
10
 Ca
2+ 
released from the SR is transferred to
mitochondria, another reservoir of Ca
2+
, via a coupling of RyR
and closely apposed mitochondrial membrane.
11
 It has been
shown that upon myocardial ischemia and reperfusion,
overload of both [Ca
2+
]
i
 and [Ca
2+
]
m
 occur and attenuation of
[Ca
2+
]
m
, but not [Ca
2+
]
i
, overload is responsible for improved
recovery in contractile functions.
12
 
Recently, many studies showed that calcium channel
blockers are the most frequently prescribed drugs for the
treatment of cardiovascular disease.
13,14
 Calcium channel
blockers are potent vasodilators, and their use in cardiovascular
treatment remains based on the blockade of Ca
2+
 mobilization.
Most specifically, some drugs including ranolazine has been
†
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shown to reverse the sustained rise in systolic and diastolic
calcium caused.
15-17
 Moreover, the special mechanism is to
inhibit late I
na
 thus preventing sodium overload of the cell. In
fact, ranolazine, currently used lactam pyridine drug for
treatment of anti-ischemia, prevents reverse mode sodium-
calcium exchange (NCX) and diastolic accumulation of
calcium possibly resulting in improved diastolic tone and
improved coronary blood flow. And, it has been shown to
decrease post-ischemic contracture in rabbit isolated perfuse
hearts subjected to ischemia and reperfusion.
18-21
We hypothesized that novel lactam pyridine derivatives (Fig
1) induced the HSP70 reducing the Ca
2+
 overload and finally
may cause the myocardial cell survival as an effective
cardioprotective agent against severe hypoxia. We confirmed
that the effect of new anti-ischemia drug is lactam pyridine
derivatives on the cell survival effect.
2. Materials and Methods
2.1 Isolation and Culture of Rat Cardiomyocytes
Cardiomyocytes were prepared from Sprague-Dawley
neonatal rat hearts. To deplete red blood cells, isolated heart
tissues were washed with Dulbecco’s phosphate-buffered
saline solution (pH 7.4, Invitrogen). Hearts were minced with
micro-dissecting scissors to 0.5 mm
3
 and treated with 4 ml of
collagenase II (1.4 mg/ml 270 units/mg, Invitrogen) for 5
minutes in a 37
o
C humidified chamber. The supernatant was
removed and washed with 10% FBS DMEM. Cell pellets were
obtained by centrifugation, and resuspended in an equal
volume of fresh medium containing 10% FBS. Remaining
tissue was treated with fresh collagenase II solution for an
additional 5 minutes. The incubation procedure was repeated
until tissue was totally digested. The resulting supernatant was
centrifuged at 2000 rpm for 2 minutes at room temperature. The
cell pellet was resuspended in 5 ml of cell culture medium and
plated for 2 hours at 37
o
C in a 5% CO
2
 incubator. Non-adherent
cells were identified as cardiomyocytes. Unattached
cardiomyocytes were replated on 100 mm culture dish
(5×10
5
cell/ml) and incubated in a-MEM supplemented with
10% FBS. Cells were then cultured in a CO
2 
incubator at 37
o
C
To reduce fibroblast contamination, α-MEM with 0.1 mM 5-
bromo-2’-deoxyuridine (Brd-U) (Sigma) was used.
22-23
2.2 Measurement of Cytosolic Free Ca
2+
The measurement of cytosolic free Ca
2+
concentration was
estimated by confocal microscopy analysis. Neonatal rat
cardiomyocytes were plated on a four well slide chamber
coated with 1.5% gelatin for 1 day in α-MEM containing 10%
fetal bovine serum (Gibco BRL) and 0.1 µM BrdU (Sigma).
After incubation, cells were washed with modified Tyrode's
solution with 0.265 g/L CaCl
2
, 0.214 g/L MgCl
2
, 0.2 g/L KCl,
8.0 g/L NaCl, 1 g/L glucose, 0.05 g/L NaH
2
PO
4
, and 1.0 g/L
NaHCO
3
. Cells were then loaded with 10 µM acetoxymethyl
ester fluo-4 (Fluo-4 AM, Molecular Probe) for 20 minutes, at
37
o
C, in the dark. Fluorescence images were collected using
confocal microscope excited by 488 nm argon laser and emitted
light was collected through a 510-560 nm band-pass filter. The
relative intracellular Ca
2+
 concentration was determined by
measuring fluorescent intensity. 
2.3 MTT Assay
NRVCMs were plated in triplicate wells of 96 well plates at
a density of 5×10
4 
cells
 
per well. 90% confluent NRVCMs were
fed with 10% FBS DMEM. The NRVCMs were placed in the
hypoxia chamber and washed twice by degassed serum-free
DMEM. After degassed fresh serum-free DMEM were
exchanged, cells incubated under hypoxia. Time dependently
incubation was performed, the incubation period, 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) solution (Sigma, USA) was added to each well to a final
concentration of 0.5 mg/mL and was incubated at 37
o
C for 2
hours to allow MTT reduction. The formazan crystals were
dissolved by adding dimethylsulfoxide (DMSO) and
absorbance  was  m easured a t  the  570 nm wi th a
spectrophotometer. Experiments were performed in triplicate.
2.4 RT-PCR Analysis
Total RNA was prepared using the Ultraspect™-II RNA
system (Biotecx Laboratories Inc.) and single-stranded cDNA
was synthesized from isolated total RNA by Avian
myeloblastosis virus (AMV) reverse transcriptase. A 20 µl
reverse transcription reaction mixture containing 1 µg of total
RNA, 1X reverse transcription buffer (10 mM Tris–HCl, pH
Figure 1. Chemical structure of a lactam pyridine derivative SK-
D80375.
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9.0, 50 mM KCl, 0.1% Triton X-100), 1 mM deoxynucleoside
triphosphates (dNTPs), 0.5 unit of RNase inhibitor, 0.5 µg of
oligo(dT)15, and 15 units of AMV reverse transcriptase were
incubated at 42
o
C for 15 minutes, heated at 99
o
C for 5 minutes,
and then incubated at 4°C for 5 minutes. PCRs were performed
for 30 cycles with 3’ and 5’ primers shown in Table 1. GADPH
was used as an internal standard. The amplification product
signal intensity was normalized to its respective GADPH signal
intensity.
2.5 Immunoblot Analysis
Cells were washed once in PBS and lysed in buffer (Cell
Signaling Technology) containing 20 mM Tris (pH 7.5),
150 mM NaCl, 1 mM Na
2
-EDTA, 1 mM EGTA, 1% Triton, 2.5
mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM
Na
3
VO
4
, 1 mg/ml leupeptin, and 1 mM phenylmethylsulfonyl
fluoride. Protein concentrations were determined using the
Bradford Protein Assay Kit (Bio-Rad). Proteins were separated
in a 12% sodium dodecyl sulfate-polyacrylamide gel and
transferred to a polyvinylidene difluoride membrane
(Millipore). After membrane blocking with Tris-buffered
saline-Tween 20 (TBS-T, 0.1% Tween 20) containing 5%
nonfat dried milk for 1 hour at room temperature, the
membrane was washed twice with TBS-T and incubated with
primary antibody for 1 hour at room temperature or overnight
at 4
o
C. The membrane was washed three times with TBS-T for
10 minutes and incubated for 1 hour atroom temperature with
horseradish peroxidase-conjugated secondary antibodies. After
extensive washing, bands were detected by enhanced
chemiluminescence reagent (Santa Cruz Biotechnology). Band
intensities were quantified using the Photo-Image System
(Molecular Dynamics).
2.6 Myocardial Infarction Induction and SK-D80375
Injection
All animal experimental procedures were approved by the
Committee for Care and Use of Laboratory Animals, Yonsei
University College of Medicine, and performed in accordance
with Guidelines and Regulations for Animal Care. Myocardial
infarction was produced in male Sprague-Dawley rats
(200±30 g) by left anterior descending coronary artery surgical
occlusion, according to previously described procedures.
Briefly, after anesthesia with ketamine (10 mg/kg) and xylazine
(5 mg/kg), hearts were exteriorized by opening the chest at the
third and fourth ribs. After 1 hour of occlusion, ischemic heart
was reperfused. SK-D80375 was injected by intra-peritoneally
at everyday. 
2.7 Echocardiography
The rats were sedated with zoletil (50 mg/kg) and xylazine
(5 mg/kg), both of which were given intraperitoneally. Imaging
was performed at 15 MHz with a linear transducer interfaced
with an ultrasound system (Vivid 7, GE Vingmed Ultrasound,
Horten, Norway). Images were acquired in a parasternal short
axis view and all data were recorded and, subsequently,
analyzed at the end of the study. For each animal, the LV end-
systolic dimensions (LVESD) and LV end-diastolic dimensions
(LVEDD) were measured from the M-mode tracings, and the
LV shortening fraction (FS), ejection fraction (EF) were
calculated.
2.8 Statistical Analysis
Data are expressed as means±SE. Statistical analysis of two
Table 1. PCR primers used in this study.
Primer sequence
NCX
TGTCTGCGATTGCTTGTCTC
TCACTCATCCACCAGACG
PMCA4
AGCAGTTGCGTCAGTCAGAA
GCTTTGTAGAGGGCTGTTGG
CREM
CCGTATGACCATGGAAACAG
CAGGTCCAAGTCAAACACAG
SERCA
TCCATCTGCCTGTCCAT
GCGGTTACTCCAGTATTG
GAPDH
CTCCCAACGTGTCTGTTGTG
TGAGCTTGACAAAGTGGTCG
Figure 2. Measurement of cardiomyocyte viability during
hypoxia. Cardiomyocytes were incubated in the absence or pres-
ence of SK-D80375 under hypoxia for 24 hr. 1-10 µM SK-
D80375 were simultaneously treated with hypoxia (less than 1%
O
2
). Cell survival rate was detected by MTT assay. Each bar
came from six wells of 96-well plate and represented the
mean±SE. 
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groups were estimated by Student´s t-test. Across group
analysis was performed with one-way ANOVA, using the
Bonferroni test. A p <0.05 was considered significant.
3. Results
3.1 Effect of SK-D80375 on Cell Survival in Hypoxic
Cardiomyocytes
To determine the effects of SK-D80375 on survival of
cardiomyocytes under hypoxic conditions, we evaluated the
survival rate of hypoxic cardiomyocytes. The structure of SK-
D80375 is shown in Fig 1. As shown in Fig 2, cell survival was
significantly increased in SK-D80375-treated hypoxic
cardiomyocytes compared to untreated controls. In particular,
2.5-5 µM concentration of SK-D80375 have shown the highest
effect on cell survival.
3.2 Effect of SK-D80375 on Cytosolic Ca
2+
 Overload in
Hypoxia
Altered Ca
2+
 homeosasis play important roles in hypoxia-
induced cardiomyocytes injury. To know whether SK-D80375
treatment decreased intracellular Ca
2+
 overload in hypoxic
cardiomyocytes, the intracellular Ca
2+
 level was examined
using the fluo-4. As shown in Fig 3, the intracellular Ca
2+
during hypoxia was increased about 1.5-fold at 2 hours after
hypoxia, which was significantly decreased by treatment with
2.5 µM SK-D80375 (39±2.5%). 
Figure 3. Effects of SK-D80375 on intracellular Ca
2+
 concentra-
tion. Confocal fluorescent images of neonatal rat cardiomyocytes
were obtained by loading with fluo-4 AM. The cells with SK-
D80375 were incubated in an anaerobic chamber for 24 hr. The
mean±SE of eight independent experiments is reported
(##p<0.001 vs hypoxia and *p<0.05 vs hypoxia).
Figure 4. Effects and SK-D80375 on Ca
2+
 regulating proteins. Expression levels of the SERCA2a, PMCA4, CREM and NCX were esti-
mated in cardiomyocytes subjected to Hypoxia with or without SK-D80375 and analyzed (**p<0.001 vs control and ##p<0.001 vs
hypoxia). 
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3.3 SK-D80375 Regulates the Ca
2+
 Channel Expression
Since various calcium handling proteins are associated with
the intracellular Ca
2+
 levels in cardiomyocytes, we investigated
the alteration of those proteins in hypoxic cardiomyocytes by
RT-PCR. The expression level of SERCA2a was decreased in
hypoxic cardiomyocytes, which was significantly rescued by
SK-D80375 treatment. In addition, the expression levels of
other calcium regulating proteins such as, PMCA4, CREM,
and NCX were significantly increased in cardiomyocytes by
hypoxic stress. These alterations were also rescued by SK-
D80375 (Fig 4). These result demonstrated that SK-D80375
protects apoptosis of cardiomyocytes through the maintaining
Ca
2+
 homeostasis. 
3.4 Effect of SK-D80375 on the Expression of Heat
Shock Protein 70 (H
SP
70)
Since H
SP
70 mediated cardiac protection from ischemic
injury and restored Ca
2+
 homeostasis,
21
 we examined the effect
of SK-D80375 on H
SP
70 induction in hypoxic cardiomyocytes.
Although the expression of H
SP
70 was increased by 24 hours
hypoxia as shown in Fig 5, H
SP
70 was increased by SK-
D80375 treatment with more than that of hypoxia only. The
induction of H
SP
70 was observed at 1-10 µM concentrations of
SK-D80375 and the highest induction was caused by 2.5 µM
treatment.
3.5 Effect of SK-D80375 on the Heart Function
Heart function was estimated by echocardiographic analysis
of the rat heart one week after ischemia and the administration
of therapeutics, SK-D80375. There were three groups (n=5/
group): control, MI, MI+SK-D80375. The results from the
echocardiographic examinations were compared between the
control group and experimental animal groups. LV function and
remodeling indices are summarized in Table 2. LV ejection
fraction and LV fractional shortening were improved by
treatment with SK-D80375 (3 mg/kg) in the MI+SK-D80375
group relative to the MI group (Fig 6).
4. Discussion
In the previous study, we showed that maternal
administration of 2 hours of hypoxic condition caused
apoptotic cell death in rat heart in vivo in a dose-dependent
manner.
24
 However, the effect of hypoxia may be more
complex because hypoxia may have direct effects on the
cardiovascular system and may cause cardiac ischemia.
Although it cannot be excluded that other factors may be
involved in maternal hypoxic stress mediated heart apoptosis,
we have shown that ischemic condition induces calcium
Figure 5. Effects of SK-D80375 on expression of hsp70. Cardi-
omyocytes were subjected to hypoxia with or without SK-
D80375 for 24 hr. HSP70 was treated during hypoxia and was
detected by immunoblotting (**p<0.001 vs control and
##p<0.001 vs hypoxia). 
Figure 6. Two-dimensional-echocardiography of left ventricle. Each value is the mean±SE of the five independent experiments
(**p<0.001 vs control and ##p<0.001 vs MI). 
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overload level in cardiomyocytes in this study. Given the
finding that hypoxia induced apoptosis in cultured neonatal rat
cardiomyocytes; it is likely that there is a connection between
myocardial hypoxia and cardiomyocyte apoptosis in vitro in the
present study. Ranolazine is a brightly anti-anginal drug for
cardiac therapy.
25
 It is a racemic mixture composed with
aromatic and pyridine. A lactam ring is part of the structure of
several antibiotic families.
24
 for example, penicillins,
cephalosporins, and monobactams. Pyridine is a simple
aromatic heterocyclic organic compound with the chemical
formula C
5
H
5
N used as a precursor to pharmaceuticals. 
We observed that the effects of lactam ring and pyridine
combined drugs on cell survival are higher than ranolazine.
And, we demonstrated that new lactam pyridine derivatives,
SK-D80375 had an effect as a new anti-ischemia drugs. As
shown in Fig 2, the hypoxic cell death was reduced in
cardiomyocytes treated with SK-D80375 with dose-dependent
manner. During hypoxia, intracellular Ca
2+ 
caused by activation
of several calcium channels and pumps is increased in various
cells including cardiomyocytes.
6
 To address the role of SK-
D80375 about Ca
2+ 
homeostasis in hypoxic conditions,
intracellular Ca
2 +
 level was estimated in hypoxic
cardiomyocytes. As shown in Fig 3, the intracellular Ca
2+ 
was
increased about 1.5-fold in hypoxia only, which was
significantly decreased by treatment with SK-D80375. We also
examined the expression levels of calcium-related proteins in
cardiomyocytes (Fig 4). We observed that the expression levels
of Ca
2+
 regulating proteins include NCX, PMCA4 and CREM
are altered in hypoxic cardiomyocytes , but those altered levels
were restored to normal levels in SK-D80375 treated
cardiomyocytes. In fact, the Ca
2+
 regulating proteins include
NCX, PMCA4 and CREM plays a major role in Ca
2+
homeostasis and contributes to abnormal intracellular Ca
2+
handling in a failing heart.
8 
Entry of Ca
2+
 triggers further release
the Ca
2+ 
via ryanodine receptor (RyR) in the SR, leading to a
sudden increase in [Ca
2+
]
i
.
10
 The NCX activity is also increased
after preconditioning as indicated by a shorter decay time of the
[Ca
2+
]i, and a greater activity determined in the Ca
2+
 flux study. 
Heat shock proteins (HSP) are a family of proteins induced
by an increase in temperature as well as other environmental
stresses and are well known to play a role in protein folding,
translocation, and the assembly of intracellular protein, which
may protect against various environmental challenges.
26
 Hsp70
(70 kDa family of HSP) is one of the most extensive studied
groups. Some studies have shown that over-expression of
Hsp70 allows protection against simulated ischemia and
metabolic stress.
27
 In particular, up-regulation of the inducible
Hsp70 ameliorated cardiomyocyte function in the presence of
calcium overload. Despite this evidence, the exact mechanism
of HSP-mediated myocardial protection remains unknown.
28-29
In normal conditions, Hsp70 family members function as
molecular chaperones by assisting in folding and assembly of
newly synthesized proteins and by transporting these proteins
to various organelles.
28
 Upon stress such as heat, which induces
cell death, the inducible form Hsp70 is activated and protects
the cell from apoptosis.
29
 Although the expression of Hsp70
was increased in cardiomyocytes by hypoxia as shown in Fig 5,
Hsp70 was more induced in cardiomyocytes treated with
2.5 µM SK-D80375 than that of hypoxia only. 
Heart function was estimated by echocardiographic analysis
in one week after ischemia and the administration of
therapeutics, SK-D80375. There were three groups (n=5/
group): control, MI and MI+SK-D80375. The results from the
rat echocardiography were compared between control group
and experimental animal groups. Cardiac function was directly
assessed in this study, and echocardiographic studies have
shown restored cardiac contractility after treatment with SK-
D80375 (Fig 6, Table 2)
The SK-D80375 on hypoxic condition brought about the
reduction of calcium overload in cardiomyocytes. It is
postulated that therapy with SK-D80375 could prove useful in
attenuating cardiac remodeling and in reducing the
development of calcium overload in myocardial infarction.
5. Conclusion
This study suggests that SK-D80375 could be useful in
attenuating cardiac remodeling and in reducing the
Table 2. Echocardiography.
Variables Control (n=5) MI (n=5) MI-375 (n=5)
HR, bpm 192.67±8.00 189.56±10.77 212±17.00
LVIDd, mm 7.33±0.00 10.33±1.34† 8.50±0.50
LVIDs, mm 4.44±0.23 8.44±1.56† 6.00±1.00
IVSd, mm 1±0.00 0.67±0.33 100±0.00
IVSs, mm 2.00±0.33 1.33±67 1.50±0.50
LVPWd, mm 1.56±0.11 1.11±0.22 1.50±0.50
LVPWs, mm 2.22±0.11 1.56±0.44 2.50±0.50
FS, % 39.22±1.45 15.45±12.55† 26.50±6.50∫∫
LVEF, 75.00±1.67 35.22±24.45‡ 6.100±6.00∫
Each value is given as mean±SE. LVIDd= left ventricular internal
diameter in diastole, LVIDs= left ventricular internal diameter in
systole, IVSd= interaventricular septum in diastole, IVSs= intera
ventricular septum in systole, LVPWd= left ventricular posterior
wall in diastole, LVPWs= left ventricular posterior wall in systole,
FS=fractional shortening, LVEF=left ventricular ejection fraction
(†p<0.01 vs Control, p<0.01 vs MI, p<0.05 vs MI).
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development of calcium overload in myocardial infarction.
Echocardiographic studies have shown restored cardiac
contractility in diabetic model after treatment with SK-D80375.
SK-D80375 were expected as a new anti-ischemia drug for the
prevention of ischemia -mediated cardiomyocyte apoptosis. 
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